

Seroprevalence against SARS-CoV-2 in Indian populations

Prajjval Pratap Singh ¹, Gyaneshwer Chaubey ² and Serosurveillance consortium
Banaras Hindu University, Varanasi, India (full author list has been provided at the end
of the manuscript)

¹ Cytogenetics laboratory, Department of Zoology, Banaras Hindu University, Varanasi,
India-221005

Keywords: Antibody, Coronavirus, India, Seroprevalence, Herd immunity

Abstract

Infection born by Coronavirus SARS-CoV-2 has swept the world within a time of a few months. It has created a devastating effect on humanity with social and economic depression. Europe and America were the hardest hit continents. India has also lost lives, making the country fourth most deadly worldwide. However, the infection and death rate per million and the case fatality ratio in India were substantially lower than in many developed nations. Several factors have been proposed including genetics. One of the important facts is that a large chunk of Indian population is asymptomatic to the SARS-CoV-2 infection. Thus, the real infection in India is much higher than the reported number of cases. Therefore, the majority of people are already immune in the country. To understand the dynamics of real infection as well as the level of immunity against SARS-CoV-2, we have performed antibody testing (serosurveillance) in the urban region of fourteen Indian districts encompassing six states. In our survey, the seroprevalence frequency varied between 0.01-0.48, suggesting high variability of viral transmission between states. We also found out that the cases reported by the government were several fold lower than the real incidence of infection. This discrepancy is mainly driven by the higher number of asymptomatic cases. Overall, we suggest that with the high level of immunity developed against SARS-CoV-2 in the majority of the districts, the case fatality rate of second wave in India will be minor than first wave.

Introduction

The whole world has been fighting the COVID-19 epidemic for over a year. During this time, the number of people who died due to infection of this virus around the globe has also crossed the mark of 2 million (Dong et al., 2020). Before the roll-out of vaccination recently, it was highly challenging for a nation to stop the spread of this virus. Several of the standard precautionary measures, e.g. strict lockdown, the use of masks, frequent hand hygiene, social distancing, contact tracing and quarantine have been applied widely (Jung et al., 2020; Rodriguez-Palacios et al., 2020). Even so, virtually no country is yet able to declare itself completely free from the virus. Initially, herd immunity was also considered and widely discussed (Randolph and Barreiro, 2020; Slot et al., 2020).

Herd immunity against the SARS-CoV-2 is one of the highly debated topics (Anderson and May, 1985; Bock et al., 2020; Frederiksen et al., 2020; Jung et al., 2020; Kwok et al., 2020; Neagu, 2020). During a pandemic, when approximately 70% of the population get infected and develop antibodies against the pathogen, herd immunity should theoretically be attained. This barrier of immunity blocks the virus and adds passive immunity to non-infected people. However, due to the high fatality rate of SARS-CoV-2 infection, nearly all countries did not adopt this strategy. For example, the United Kingdom and Sweden opted for it, with the UK abandoning it at the initial stage (Hunter, 2020; Sibony, 2020), and Sweden was heavily criticised for thereby incurring the largest number of cases and fatalities in Scandinavia (Habib, 2020; Orłowski and Goldsmith, 2020). Thus, Tegnell's plan of obtaining rapid herd immunity for Sweden indeed turned out to be a case of autophagy (Chaubey, 2020).

The model of herd immunity is very similar to the positive selection (or selective sweep), a term often used in the genomic studies (Sabeti et al., 2002; Voight et al., 2006). Similarly, we can also relate hard sweep and soft sweep terminology (Pritchard et al., 2010), for a soft and hard herd immunity. With the exclusion of hard herd immunity, the alternate option was to obtain the soft herd immunity with the strict use of defensive procedures. Protective measures like strict lockdown, the use of masks, frequent hand hygiene and social distancing have significantly reduced the effective infections and overburden to the emergency services (Aleta et al., 2020; West et al., 2020). Also with efficacious contact tracing and quarantine, soft herd immunity may be achieved over time (Aleta et al., 2020).

From the first case in India on 30th Jan 2020, now the total cases have surpassed >10 million with >0.15 million fatalities (Coronavirus in India: Latest Map and Case Count). Although still the new number of cases tallies at between 10-15,000 per day, India has followed a perfect bell-shaped curve with a well-defined peak in September 2020. Several studies have pinpointed that the real number of infected people in a population are several fold higher than the reported cases (Aspelund et al., 2020; Böhning et al., 2020; Ivorra et al., 2020; Mukhopadhyay and Chakraborty, 2020; Pedersen and Meneghini, 2020; Shaman, 2020). In addition, a large number of asymptomatic people add another layer of complexity, as has been seen in the case of India (Chaubey, 2020). Most studies relied upon mathematical modelling, which may not show the real picture of COVID-19 in India (Arti and Bhatnagar, 2020; Chatterjee et al., 2020a, 2020b; Mukhopadhyay and Chakraborty, 2020; Tiwari, 2020). Random antibody testing in a population is one of the procedures to obtain a real-time picture of the developed immunity. Thus, to understand the COVID-19 dynamics in India, we have performed real-time antibody testing on urban populations from fourteen districts of India. The aim was to estimate the level of immunity against COVID-19 among urban street vendors.

Materials and Methods

Since most of the COVID-19 cases in India were concentrated on urban areas, we concentrated on urban populations in our survey. During the month of September-December 2020, we randomly surveyed healthy working individuals who have neither been diagnosed with COVID-19, nor had been sick with any associated symptom in the recent past. Moreover, we excluded those individuals in our survey whose family members have ever been diagnosed with the COVID-19 in the past. Our focus was to screen people from urban vendor group who are relatively more exposed in society, e.g. roadside workers, roadside fruit-vegetable sellers, rikshaw pullers, autorickshaw drivers, milkmen, hawkers etc. With these stringent criteria, we screened unrelated people who have not lived together. Informed consent were obtained from all the participants. Study was approved by the ethical committee of Banaras Hindu University, Varanasi, India.

We used Coviscreen™ kit, kindly provided by Biosense Technologies, India to screen the individuals for the presence of antibodies. This kit detects the total antibodies

(IgM+IgA+IgG) present in the blood. We followed the manufacturers protocol for detection. A sample test for positive and negative samples is shown in Figure 1a. Complete details about this kit can be obtained from the supplier <http://www.tulipgroup.com/Covid19/Covid19.html>.

The frequency of antibody positive individuals were calculated in each of the districts surveyed (Table 1). The district-wise geographical frequency map was generated by <https://www.datawrapper.de/> (Fig. 1b). The frequency bar plot of each district was drawn with 95% CI (Figure 1c). District-wise population census data were extracted from the 2011 census of India (Census of India Website: Office of the Registrar General & Census Commissioner, India). Numbers of reported cases in each district were recorded from the Covid India tracker (Coronavirus in India: Latest Map and Case Count). This study has been approved by the Institutional Ethical Committee of Banaras Hindu University, Varanasi, India.

Results and Discussion

In our survey, geographically we have covered districts from Western, Northern, Eastern, Central and Southern regions of India. Two districts were covered from Western part (Gujarat), seven districts were surveyed in Northern part (Uttar Pradesh), three districts from Central part (Madhya Pradesh and Chhattisgarh), whereas a single district each of Eastern (West Bengal) and Southern (Karnataka) regions were surveyed (Table 1). Our seroprevalence survey in fourteen districts of six states has shown a high level of variability between regions (Fig. 1b,c). The minimum proportion of antibody-positive people was observed in Raipur district of Chhattisgarh state, whereas the maximum proportion of antibody-positive individuals was found in Ghazipur district of Uttar Pradesh state (Figure 1b,c and Table 1). The mean seroprevalence among studied districts was 0.306 (95%CI 0.287-0.325). The high prevalence of antibodies in many of the districts suggests that soft herd immunity in India is well underway. The frequency of antibody-positive people is sporadic, however, with regions like eastern Uttar Pradesh showing a largely uniform seroprevalence (Figs. 1b,c). The mean value in this region was found to be 0.41 (95%CI 0.38-0.44). Major districts of this region like Varanasi, Jaunpur and Ghazipur all had a frequency of >0.40 seroprevalence. The variation among districts suggests that the level of virus spread among districts of India is asymmetrical. The low seroprevalence regions may hit by another wave.

Notably, all the participants in this study were found to be asymptomatic, they did not know that they ever had COVID-19. This suggests that a large proportion of the Indian population is asymptomatic against SARS-CoV-2 infection. Indeed, there might be several known and unknown reasons behind this phenomenon. However the prevalence of the rs2285666-associated haplotype (Srivastava et al., 2020) and the fact that ~65% of the Indian population is 35 years of age or younger are two highly likely explanations.

In order to understand the magnitude of unreported cases, we have compared the frequency of government-reported cases with the frequency of antibody-positive cases. All of the districts showed higher seroprevalence than the reported cases (Table 1). The mean value of studied districts was 17 times (95% CI 13-22) higher than the government reported cases. Similar with the frequency dissimilarities, in a state-wise comparison, we observed substantial differences, e.g. 40 times in Gujarat, 21 times in Uttar Pradesh, 23 times in Madhya Pradesh, 0.2 times in Chhattisgarh, 9 times in West Bengal and 5 times in Karnataka. Interestingly, we found out that cases reported by the government were highly correlated with the urban census (two tailed $p < 0.0001$), whereas we did not find any significant correlation between antibody-positive frequency with the urban census or government-reported cases.

As our result suggests that the number of real infections in India is several fold higher than the government-reported cases, we may reconsider the case fatality ratio (CFR). The present case fatality ratio of India (1.44) is significantly lower (two tailed p value < 0.0001) than the global average (2.15). Considering our result, which shows a far greater number of real infected people, the actual case fatality ratio of India is at least 17 times lower (Table 1).

Our observation at the fourteen districts of India indicates a sporadic high level of immunity among people who are highly contagious as well as exposed. Since our focus was on people who are more prone to receive as well as spread infection, our result indicates that a strong level of immunity wall has already come into effect. In this apparently unfolding scenario, it is likely that most of the hotspots are saturated with the immune people. The projected second wave may appear possibly due to new hotspots as well as more contagious new virus strains, however with the large number of immune people the impact of second wave will be moderate and sporadic than the

first wave. This may substantially reduce the case fatality ratio in second wave than the first wave.

In summary, for the first time we have used a novel approach to estimate the developed level of immunity against SARS-CoV-2 among the exposed populations of fourteen districts. These results strongly indicate that soft herd immunity is already in force in several of the Indian territory. We observed that on an average every third street vendor in the majority of the districts studied have developed antibodies against SARS-CoV-2. The number of asymptomatic cases in India is much higher than expected. Overall, we suggest that with the high level of immunity developed against SARS-CoV-2 in the majority of districts, it is unlikely to have a higher case fatality rate during second wave in India.

Acknowledgements

We are grateful to the Biosense Technologies, India for their kind help in this project. We thank Prof. George van Driem for his constructive comments. We did not receive any specific funding for this project.

Author Contributions

GC conceived and designed this study. Serosurveillance consortium Banaras Hindu University, Varanasi, India collected the data from different regions of India. PPS, RK, MKS, AP, and GC analysed the data. PPS and GC wrote the manuscript from the inputs of other co-authors. All authors contributed to the article and approved the submitted version.

Data Availability Statement

All datasets generated for this study are included in the article/Supplementary Material.

Competing interests

The authors declare no competing interests.

Conflict of Interest

Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

References

- Aleta, A., Martin-Corral, D., y Piontti, A. P., Ajelli, M., Litvinova, M., Chinazzi, M., et al. (2020). Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. *Nat. Hum. Behav.* 4, 964–971.
- Anderson, R. M., and May, R. M. (1985). Vaccination and herd immunity to infectious diseases. *Nature* 318, 323–329.
- Arti, M. K., and Bhatnagar, K. (2020). Modeling and predictions for COVID 19 spread in India. *No April*.
- Aspelund, K. M., Droste, M. C., Stock, J. H., and Walker, C. D. (2020). Identification and estimation of undetected COVID-19 cases using testing data from Iceland. National Bureau of Economic Research.
- Bock, W., Adamik, B., Bawiec, M., Bezborodov, V., Bodych, M., Burgard, J. P., et al. (2020). Mitigation and herd immunity strategy for COVID-19 is likely to fail. *medRxiv*.
- Böhning, D., Rocchetti, I., Maruotti, A., and Holling, H. (2020). Estimating the undetected infections in the Covid-19 outbreak by harnessing capture–recapture methods. *Int. J. Infect. Dis.* 97, 197–201.
- Census of India Website: Office of the Registrar General & Census Commissioner, India Available at: <https://censusindia.gov.in/2011-common/censusdata2011.html> [Accessed January 5, 2021].
- Chatterjee, K., Chatterjee, K., Kumar, A., and Shankar, S. (2020a). Healthcare impact of COVID-19 epidemic in India: A stochastic mathematical model. *Med. J. Armed Forces India* 76, 147–155.
- Chatterjee, S., Sarkar, A., Chatterjee, S., Karmakar, M., and Paul, R. (2020b). Studying the progress of COVID-19 outbreak in India using SIRD model. *Indian J. Phys.*, 1–17.
- Chaubey, G. (2020). Coronavirus (SARS-CoV-2) and Mortality Rate in India: The Winning Edge. *Front. Public Health* 8, 397. doi:10.3389/fpubh.2020.00397.
- Coronavirus in India: Latest Map and Case Count Available at: <https://www.covid19india.org> [Accessed May 13, 2020].
- Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect. Dis.*
- Frederiksen, L. S. F., Zhang, Y., Foged, C., and Thakur, A. (2020). The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. *Front. Immunol.* 11.

- Habib, H. (2020). Has Sweden's controversial covid-19 strategy been successful? *bmj* 369.
- Hunter, D. J. (2020). Covid-19 and the stiff upper lip—The pandemic response in the United Kingdom. *N. Engl. J. Med.* 382, e31.
- Ivorra, B., Ferrández, M. R., Vela-Pérez, M., and Ramos, A. M. (2020). Mathematical modeling of the spread of the coronavirus disease 2019 (COVID-19) taking into account the undetected infections. The case of China. *Commun. Nonlinear Sci. Numer. Simul.* 88, 105303.
- Jung, F., Krieger, V., Hufert, F. T., and Küpper, J.-H. (2020). Herd immunity or suppression strategy to combat COVID-19. *Clin. Hemorheol. Microcirc.*, 1–5.
- Kwok, K. O., Lai, F., Wei, W. I., Wong, S. Y. S., and Tang, J. W. (2020). Herd immunity—estimating the level required to halt the COVID-19 epidemics in affected countries. *J. Infect.* 80, e32–e33.
- Mukhopadhyay, S., and Chakraborty, D. (2020). Estimation of undetected COVID-19 infections in India. *medRxiv*.
- Neagu, M. (2020). The bumpy road to achieve herd immunity in COVID-19. *J. Immunoassay Immunochem.*, 1–18.
- Orlowski, E. J., and Goldsmith, D. J. (2020). Four months into the COVID-19 pandemic, Sweden's prized herd immunity is nowhere in sight. *J. R. Soc. Med.* 113, 292–298.
- Pedersen, M. G., and Meneghini, M. (2020). Quantifying undetected COVID-19 cases and effects of containment measures in Italy. *Res. Prepr. Online 21 March 2020 DOI* 10.
- Pritchard, J. K., Pickrell, J. K., and Coop, G. (2010). The Genetics of Human Adaptation: Hard Sweeps, Soft Sweeps, and Polygenic Adaptation. *Curr Biol* 20, R208–R215. doi:10.1016/j.cub.2009.11.055.
- Randolph, H. E., and Barreiro, L. B. (2020). Herd immunity: understanding COVID-19. *Immunity* 52, 737–741.
- Rodriguez-Palacios, A., Cominelli, F., Basson, A., Pizarro, T., and Ilic, S. (2020). Textile Masks and Surface Covers-A'Universal Droplet Reduction Model'Against Respiratory Pandemics. *medRxiv*.
- Sabeti, P. C., Reich, D. E., Higgins, J. M., Levine, H. Z., Richter, D. J., Schaffner, S. F., et al. (2002). Detecting recent positive selection in the human genome from haplotype structure. *Nature* 419, 832–7.
- Shaman, J. (2020). *An estimation of undetected COVID cases in France*. Nature Publishing Group.
- Sibony, A.-L. (2020). The UK COVID-19 Response: A Behavioural Irony? *Eur. J. Risk Regul.*, 1–11.

- Slot, E., Hogema, B. M., Reusken, C. B., Reimerink, J. H., Molier, M., Karregat, J. H., et al. (2020). Herd immunity is not a realistic exit strategy during a COVID-19 outbreak.
- Srivastava, A., Pandey, R. K., Singh, P. P., Kumar, P., Rasalkar, A. A., Tamang, R., et al. (2020). Most frequent South Asian haplotypes of ACE2 share identity by descent with East Eurasian populations. *PLoS ONE* 15, e0238255. doi:10.1371/journal.pone.0238255.
- Tiwari, A. (2020). Modelling and analysis of COVID-19 epidemic in India. *J. Saf. Sci. Resil.* 1, 135–140.
- Voight, B. F., Kudravalli, S., Wen, X., and Pritchard, J. K. (2006). A map of recent positive selection in the human genome. *PLoS Biol* 4. doi:10.1371/journal.pbio.0040072.
- West, R., Michie, S., Rubin, G. J., and Amlôt, R. (2020). Applying principles of behaviour change to reduce SARS-CoV-2 transmission. *Nat. Hum. Behav.* 4, 451–459.

Figure Legend:

Figure 1a. The detection of antibodies by the Coviscreen™ kit. The kit produce one and two bands in case of Antibody negative and positive persons respectively.

Figure 1b. The geospatial frequency of antibodies with our sampling locations.

Figure 1c. The bar plot showing seroprevalence frequency (CI95%) among studied districts. The districts are also grouped in to states.


Table 1. The detailed districtwise data of seroprevalence. Frequency of Government cases has been calculated by number of reported cases/urban census. Number of times were calculated by dividing seroprevalence with frequency of Government reported cases.

State	District	Months	N	Antibody+	Freq.(Ab+)	Freq.(Govt.)	Cases (Govt.)	Urban Census	Times
Gujarat	Ahmedabad	Dec-20	50	23	0.46 (0.329-0.597)	0.011	60848	5600000	42.3
Gujarat	Baroda	Dec-20	50	14	0.28 (0.175-0.417)	0.017	27755	1671000	16.9
Uttar Pradesh	Varanasi	Sept 2020-Dec 2020	406	166	0.409 (0.362-0.457)	0.012	23360	2000000	35.0
Uttar Pradesh	Jaunpur	Sept 2020-Dec 2020	263	116	0.441 (0.382-0.502)	0.019	6697	347000	22.9
Uttar Pradesh	Ghazipur	Sept 2020-Dec 2020	128	61	0.477 (0.392-0.563)	0.043	5236	121000	11.0
Uttar Pradesh	Mirzapur	Oct-20	100	30	0.30 (0.219-0.396)	0.014	3441	246000	21.4
Uttar Pradesh	Gorakhpur	Oct-20	98	38	0.388 (0.297-0.487)	0.031	21364	695000	12.6
Uttar Pradesh	Lucknow	Oct-20	72	27	0.375 (0.272-0.491)	0.029	81276	2817000	13.0
Uttar Pradesh	Jhansi	Nov-20	100	7	0.07 (0.035-0.138)	0.019	10399	548000	3.7
Madhya Pradesh	Sagar	Sept 2020-Dec 2020	250	98	0.392 (0.334-0.454)	0.015	5367	370000	27.0
Madhya Pradesh	Singrauli	Sept 2020-Oct 2020	384	59	0.154 (0.121-0.193)	0.008	1907	227000	18.3
Chhattishgarh	Raipur	Sep-20	100	1	0.01 (0.002-0.054)	0.047	53106	1124000	0.2
West Bengal	Kolkata	Dec-20	100	8	0.08 (0.042-0.15)	0.009	127656	14036000	8.8
Karnataka	Mangalore	Dec-20	200	55	0.275 (0.218-0.341)	0.054	33701	624000	5.1


a



b



c



Full author list-

Prajval Pratap Singh^{1*}, Rakesh Tamang^{2*}, Manoj Kumar Shukla^{3*}, Abhishek Pathak^{4*}, Anshika Shrivastava¹, Pranav Gupta⁵, Alay Bhatt⁶, Abhishek Shrivastava⁷, Sudhir Upadhyay⁸, Ashish Singh⁹, Sanjeev Maurya⁹, Purnendu Saxena¹⁰, Vanya Singh¹, Akhilesh Kumar Chaubey¹¹, Dinesh Kumar Mishra¹², Yashvant Patel¹, Rudra Kumar Pandey¹, Ankit Shrivastava¹³, Nargis Khanam¹, Debashruti Das¹, Audditiya Bandopadhyay¹, Urgyan Chorol¹, Nagarjuna Pasupuleti¹⁴, Sachin Kumar Shrivastav¹⁴, Satya Prakash¹⁴, Indu Sharma¹⁴, Varun Sharma¹⁴, Astha Mishra^{14,15}, Pavan Kumar Dubey¹⁶, Ajit Parihar¹⁶, Priyoneel Basu¹⁷, Jaison Sequira¹⁸, Lavanya KC¹⁸, Vijayalaxmi¹⁸, Thadiyan Parambil Ijini¹⁹, Dau Dayal Aggarwal²⁰, Anand Prakash²¹, Kiran Yadav²², Anupam Yadav²², Vandana Upadhyay²³, Gunjan Mukim², Ankan Bhandari², Ankita Ghosh², Akash Kumar¹³, Vijay Kumar Yadav¹³, Kriti Nigam¹³, Abhimanyu Harshey¹³, Tanurup Das¹³, Deepa Devadas²⁴, Surendra Pratap Mishra²⁵, Ashish²⁴, Abhay Kumar Yadav²⁴, Nitish Kumar Singh²⁴, Manpreet Kaur²⁴, Sanjay Kumar¹⁷, Nikhil Srivastava¹, Charu Sharma¹, Ritabrata Chowdhury¹, Dharmendra Jain²⁶, Abhai Kumar⁴, Ritesh Shukla⁵, Raghav Kumar Mishra²², Royana Singh^{17,24}, Yamini B Tripathi³, Vijay Nath Mishra⁴, Mohammed S. Mustak¹⁸, Niraj Rai¹⁴, Sumit Kumar Rawat²⁷, Prashanth Survajhala²⁸, Keshav K Singh²⁹, Chandana Basu Mallick³⁰, Pankaj Shrivastava³¹ and Gyaneshwer Chaubey^{1#}

*Prajval Pratap Singh, Rakesh Tamang, Manoj Kumar Shukla and Abhishek Pathak - equal first author contribution

#Correspondence

¹Cytogenetics Laboratory Department of Zoology, Banaras Hindu University, India

²Department of Zoology, University of Calcutta, India

³Department of Medicinal Chemistry, Institute of Medical Science, Banaras Hindu University, India

⁴Department of Neurology, Institute of Medical Science, Banaras Hindu University, India

⁵Scangene Labs Private Limited, New Delhi, India

⁶School of Arts and Sciences, Ahmedabad University, India

⁷Mohd. Hasan P. G. College, Jaunpur, India

⁸Department of Environmental Science, Veer Bahadur Singh Purvanchal University, Jaunpur, India

⁹Genome Foundation Rural Centre Kalavari, Jaunpur, India, 222131

¹⁰VY Hospital, Raipur, Chhattisgarh, India

¹¹Krishi Vigyan Kendra, Singrauli, Jawaharlal Nehru Krishi Vishwavidyalay, Jabalpur, Madhya Pradesh, India

¹²Mishra Polyclinic, Waidhan, Madhya Pradesh, India, 486886

¹³Dr. A.P.J. Abdul Kalam Institute of Forensic Science & Criminology, Bundelkhand University, Jhansi, India

¹⁴Birbal Sahni Institutes of Palaeosciences, Lucknow, India

¹⁵Amity University, Noida, Uttar Pradesh, India

¹⁶Prosthodontics Unit, Faculty of Dental Sciences, Institute of Medical Sciences, Varanasi, India

¹⁷Multidisciplinary Research Unit, Institute of Medical Science, Banaras Hindu University, India

¹⁸Department of Applied Zoology, Mangalore University, Mangalagangothri-574199, Mangalore, Karnataka, India

¹⁹Amity Institute for Herbal and Biotech Products Development, Ravi Nagar, Peroorkada, Thiruvananthapuram, Kerala, India

²⁰Department of Biochemistry, University of Delhi, South Campus, New Delhi, India

²¹Sardar Ballabhbhai Patel College, Bhabua Kaimur, Bihar, India

²²Male Reproductive Physiology Laboratory, Department of Zoology, Banaras Hindu University, India

²³ Abhay Degree College, Varanasi, India

²⁴Department of Anatomy, Institute of Medical Science, Banaras Hindu University, India

²⁵Department of Biochemistry, Institute of Medical Science, Banaras Hindu University, India

²⁶Department of Cardiology, Institute of Medical Science, Banaras Hindu University, India

²⁷Department of Microbiology, Bundelkhand Medical College, Sagar, India

²⁸Department of Biotechnology and Bioinformatics, Birla Institute of Scientific Research Statue Circle, Jaipur, Rajasthan, India

²⁹Department of Genetics, School of Medicine, University of Alabama at Birmingham, Kaul Genetics Building, Birmingham, Alabama

³⁰Centre for Genetic Disorders, Banaras Hindu University, India

³¹DNA Fingerprinting Unit, State Forensic Science Laboratory, Department of Home (Police), Government of MP, Sagar, India